Cytokines mediate a variety of effector cell functions, including cellular proliferation, differentiation, and modulation of the immune response. Many cytokines activate receptor-associated Janus kinases (JAKs) that promote tyrosine phosphorylation of signal transducers and activators of transcription (STAT) factors. Although JAK activation has been correlated with phosphorylation, the role of this tyrosine phosphorylation in the regulation of JAK1 and JAK3 remains unclear. Furthermore, the relative roles of JAK1 and JAK3 in the activation of STAT5 by interleukin-2 (IL-2) remain poorly understood.
Background
One of the most extensively studied cytokines is interleukin-2 (IL-2), which has pleiotropic biological effects, including stimulation of the growth and differentiation of T and B lymphocytes and activation of natural killer cells (for a review, see [1] ). IL-2 acts by binding to the multimeric IL-2 receptor (IL-2R), which is composed of three transmembrane proteins. Whereas the primary role of the IL-2Rα chain is to regulate the affinity of the receptor complex for its ligand [2] [3] [4] , intracellular signaling results from the heterodimerization of the IL-2Rβ and γ c chains [5] [6] [7] . Both IL-2Rβ and γ c are members of the cytokine receptor superfamily [8] .
Heterodimerization of IL-2Rβ and γ c results in receptor phosphorylation, transcriptional activation and induction of cellular kinases (reviewed in [1] ). One of the most proximal of these events is the JAK-STAT pathway, in which receptor-activated Janus kinases (JAKs) promote the tyrosine phosphorylation of signal transducers and activators of transcription (STAT) factors (reviewed in [9] [10] [11] [12] ). The IL-2Rβ chain is constitutively associated with JAK1, whereas γ c binds JAK3 [6, 13] . Following ligand binding, JAK1 and JAK3 are activated. This activation is followed in turn by tyrosine phosphorylation of various STAT factors, including STAT1, STAT3 and STAT5 [14] [15] [16] [17] [18] [19] [20] , of which the primary target appears to be STAT5. There are two human and murine isoforms of STAT5 (STAT5A and STAT5B) that are encoded by distinct genetic loci [20] [21] [22] [23] . Following phosphorylation, STAT5 dimerizes through reciprocal phosphotyrosine-SH2 domain interactions; these dimers subsequently undergo translocation to the nucleus, where they mediate transcriptional activation. IL-2 stimulates the DNA-binding activity of both STAT5A and STAT5B [24, 25] .
In virtually all of the cellular contexts studied to date, JAK activation is critical for IL-2-mediated proliferation. A number of IL-2Rβ-chain mutants that fail to activate JAK kinases also display markedly decreased or undetectable The above evidence, as well as the behavior of other cytokine receptors, suggests that the JAKs within the IL-2R complex may contribute in different ways to downstream signaling. For instance, in the interferongamma (IFN-γ) system, JAK1 appears to have a critical role as a molecular scaffold rather than contributing a crucial enzymatic function [28] . In contrast, the kinase function of JAK2 is required for all measurable signaling properties of the IFN-γ receptor. Thus, in some cases, the JAK may primarily be required for a structural function in a cytokine receptor complex, whereas in others JAK catalytic function is strictly necessary for effective downstream signaling.
The precise mechanism by which JAKs undergo activation remains unresolved. A common site of positive regulation by phosphorylation is a region between conserved subdomains VII and VIII of the kinase domain that has been termed the activation loop (reviewed in [29] [30] [31] ). Phosphorylation in this loop may occur on tyrosine, serine or threonine residues, depending on the substrate specificity of the kinase. All four recognized members of the JAK family contain a conserved pair of tyrosines within this loop. These tyrosines appear to have a regulatory role in TYK2 and JAK2 [32, 33] .
The present studies were undertaken to determine whether the analogous tyrosines of JAK1 and JAK3 regulate the activation of these molecules. Additionally, studies were performed to determine whether the catalytic function of these JAKs is required for STAT5 induction following IL-2 binding to its receptor.
Results

STAT5A is a better substrate for JAK1 than JAK3 in vitro
There is considerable evidence that JAK1 and JAK3 are required for STAT5A and STAT5B induction following IL-2 stimulation. To test whether JAK1 and JAK3 can directly and specifically phosphorylate STAT5A, a recombinant substrate composed of the maltose-binding protein (MBP) fused to the carboxy-terminal 157 amino acids of STAT5A (MBP-STAT5A) was expressed in bacteria and purified. The MBP-STAT5A Y694F substrate contains a single amino-acid substitution at the specific tyrosine that becomes phosphorylated following cellular stimulation and is critical for STAT5 dimerization [34] . When the MBP-STAT5A substrate was incubated with activated JAK1 in vitro, vigorous tyrosine phosphorylation of this substrate was observed (Figure 1 ). In contrast, co-incubation of the MBP-STAT5A substrate with activated JAK3 produced weak phosphorylation, despite robust autophosphorylation of JAK3 itself. Coomassie staining of these protein gels demonstrated that JAK1 and JAK3 were equivalently expressed (data not shown). Despite the presence of 20 retained tyrosine residues, the MBP-STAT5A Y694F substrate was not detectably phosphorylated by either JAK1 or JAK3, suggesting that the kinase reaction does exhibit substrate specificity in vitro. Therefore, both JAK1 and JAK3 can phosphorylate STAT5A to varying degrees on the physiologically relevant tyrosine in vitro, and the critical phosphorylation site within STAT5A may be phosphorylated more avidly by JAK1 than by JAK3. 
JAK1 is regulated by phosphorylation of tyrosine residues within its activation loop
For both JAK1 and JAK3, tyrosine phosphorylation correlates with catalytic activation (reviewed in [10, 12] ), but whether these phosphorylation events are essential for JAK1 and JAK3 activation is unknown. As the activation loop of JAK1 contains two potential sites of tyrosine phosphorylation, Y1033 and Y1034 (Figure 2a) , one or both of these residues were mutated to phenylalanine. These mutants will henceforth be referred to as JAK1FF to indicate the double tyrosine to phenylalanine mutation, JAK1FY to refer to the Y1033F mutation, and JAK1YF to denote the Y1034F mutation. An enzymatically deficient JAK1 that contains an alanine substitution at the critical active-site lysine residue was also prepared (K907A). When transiently expressed in COS-7 cells, all of these mutants were expressed at levels comparable to those of the wild-type protein (Figure 2b ).
It has been previously demonstrated that overexpression of the JAKs in COS-7 or Sf9 cells results in constitutive activation and concomitant tyrosine phosphorylation ( [35, 36] ; K.D.L., data not shown). To determine the catalytic potential of these JAK1 mutants, each kinase was co-expressed with STAT5A in COS-7 cells, which results in ligand-independent STAT5A tyrosine phosphorylation and the acquisition of DNA-binding activity [24] . Such phosphorylation in this system proved specific, since co-expression of a JAK with a STAT5A molecule lacking the critically phosphorylated tyrosine (Y694F) did not result in STAT5A phosphorylation ( [34] ; data not shown). Nuclear extracts were prepared and subjected to electrophoretic mobility shift assays (EMSA) using a radiolabeled probe encoding the STAT DNA-binding site found upstream of the F c γRI gene. Co-expression of STAT5A with the wild-type JAK1 resulted in a DNAprotein complex with retarded mobility relative to the unbound probe that contained STAT5A (Figure 2c , lanes 1,2). In contrast, co-expression of the JAK1K907A mutant with STAT5A did not yield detectable STAT5A DNAbinding activity (Figure 2c, lane 3) . Similarly, the JAK1FF mutant failed to activate STAT5A, indicating that one or both of these tyrosines are critical for kinase function ( Figure 2c , lane 4). The JAK1FY and JAK1YF mutants clarified that the first tyrosine (Y1033) is required for kinase activation while the second tyrosine (Y1034) is dispensable ( Figure 2c , lanes 5,6).
It was also possible in the same system to examine JAK1 phosphorylation, which is thought to be an autocatalytic event in the context of overexpression. Expression of wild-type JAK1 or JAK1YF kinase molecules in COS-7 cells resulted in detectable phosphorylation of tyrosine residues of JAK1 ( Figure 2d ). Despite expression levels comparable to those of the wild-type protein, the JAK1K907A, JAK1FF and JAK1FY mutants failed to undergo detectable autophosphorylation. Thus, tyrosine 1033 is critical for JAK1 kinase function and may also be a site of autophosphorylation.
Activation-loop tyrosines are not absolutely required for JAK3 catalytic function
We next focused on the two analogous tyrosines within the activation loop of JAK3, Y975 and Y976 (Figure 2a ). These two tyrosines were mutated to phenylalanine to create the double mutant, JAK3FF, as well as the two single mutants, JAK3FY and JAK3YF. All of these mutants and the kinase-inactive JAK3K851A mutant were expressed in COS-7 cells at levels comparable to that of wild-type JAK3 (Figure 3a) . When co-expressed . Therefore, in contrast to JAK1, the presence of activation-loop tyrosines is not absolutely critical for the catalytic function of JAK3. However, the two single tyrosine add-back mutants suggested that the presence of the first tyrosine modestly influences JAK3 regulation, since JAK3FY failed to phosphorylate STAT5A as strongly as JAK3FF in the overexpression study ( Figure 3b , lane 5). Nonetheless, the JAK3FY mutant itself became phosphorylated on tyrosine residues when overexpressed in COS-7 cells (Figure 3c ), at levels comparable to those of wild-type JAK3. Together with the in vitro kinase data (in which JAK3 failed to phosphorylate STAT5A strongly), this result suggests that STAT5A may not be the preferred substrate for JAK3. Consequently, the subtle decrement in function of JAK3FY may be enhanced upon co-expression with STAT5A in COS-7 cells. Furthermore, both the JAK3YF and JAK3FF mutants also became tyrosine phosphorylated when overexpressed in COS-7 cells (Figure 3c ), confirming that the JAK3FF mutant retained catalytic function despite the complete absence of the regulatory-loop tyrosines. Thus, whereas JAK1 is strictly regulated via tyrosines within the activation loop, the analogous tyrosines do not play an equivalent role within JAK3. These tyrosines may nevertheless play some role in regulating catalytic function, since the JAK3FY mutant does not phosphorylate STAT5A as strongly as either wild-type JAK3 or JAK3FF, despite a potent ability to autophosphorylate.
JAK regulation involves intramolecular interactions as well as the inherent functions of the kinase domain
Because JAK1 and JAK3 are differentially regulated by activation-loop tyrosines, we next studied whether the regulation of these kinases was solely an intrinsic property of the kinase domain or whether regulation also involved other domains of the molecule. To address this question, a panel of JAK1 and JAK3 chimeras was developed ( Figure 4a ). All these constructs were expressed at equivalent protein levels when transfected into COS-7 cells, indicating equal stability (Figure 4b ). In co-expression studies with STAT5A, both of the chimeras with wild-type kinase domains, namely JAK1/3/3 and JAK3/1/1, could phosphorylate STAT5A and activate its DNAbinding activity ( Figure 4c ). As expected, neither JAK 3/1/1 KA nor JAK 1/3/3 KA, both of which contained catalytically inactive kinase domains, phosphorylated STAT5A when co-expressed in COS-7 cells (Figure 4c ). This result again demonstrated the dependence of tyrosine phosphorylation of STAT5A on the catalytic activity of the coexpressed JAK. Interestingly, the JAK3/1/1 FF chimera continued to phosphorylate STAT5A despite the loss of tyrosines within the activation loop. Therefore, the aminoterminal domain of JAK3 can confer regulation upon the kinase domain of JAK1 independent of the activationloop tyrosines since the parental JAK1FF displayed no detectable kinase activity. In contrast, the fusion of the amino terminus of JAK1 in the JAK1/3/3 FF chimera did not detectably affect the preserved activity of the JAK3FF kinase domain, as measured by the induction of STAT5A DNA-binding activity.
Whereas both wild-type JAK1/3/3 and JAK1/3/3 FF were strongly phosphorylated on tyrosine residues when overexpressed in COS-7 cells, the JAK3/1/1 FF and JAK3/1/1 FY constructs were only weakly tyrosine phosphorylated despite retaining their catalytic function (Figure 4d ). The kinase-like and kinase domains of JAK3 may contain additional sites of autophosphorylation that may not be represented in the equivalent domains of JAK1. Thus, the regulation of JAKs cannot be assigned exclusively to a single domain of the kinase but is a function of both the amino terminus and the kinase domain of the molecule. The amino terminus of JAK1 is critical for the association between IL-2Rb and JAK1
It remains unclear which domains of JAK1 are responsible for constitutive association of JAK1 with the IL-2Rβ chain. For other JAKs, the amino-terminal domain appears to be the critical determinant of receptor binding [37] [38] [39] [40] . To test this hypothesis for JAK1 and to demonstrate that the amino terminus of the JAK1/3/3 chimera was appropriately folded, IL-2Rβ was co-expressed in COS-7 cells with JAK1, JAK3, or JAK1/3/3. Both JAK1 and JAK1/3/3 were detectably and specifically co-immunoprecipitated with IL-2Rβ (Figure 5a ), demonstrating that the amino terminus of JAK1 is critical for association with IL-2Rβ. Thus, the amino terminus of JAK1 confers all of the determinants required for binding to the IL-2Rβ chain and, as its function is retained, this domain appears to be appropriately folded in the JAK1/3/3 chimera.
IL-2-dependent STAT5 activation is recapitulated by
expression of IL-2Rb, g c , JAK1, JAK3 and STAT5A in U4A
To determine the functional JAK requirements for IL-2-mediated STAT activation, we reconstituted the IL-2R in U4A cells, a somatic mutant derivative of the 2FTGH human fibrosarcoma cell line that lacks endogenous JAK1 [41] and apparently fails to express JAK3. Complementary DNAs (cDNAs) encoding IL-2Rβ, γ c , JAK1, JAK3 and STAT5A were introduced into the cells by transient co-transfection. Since STAT5A and STAT5B appear to be largely interchangeable in the context of IL-2R signaling [24] , for simplicity only the cDNA encoding analysis with an anti-STAT5 antibody confirmed that STAT5A was present in this complex ( Figure 6, lane 3) . Similar results were obtained with a probe encoding the STAT-binding site from the interferon-regulatory factor 1 (IRF-1) promoter (data not shown). To determine whether each of the five cDNAs was required for IL-2-mediated STAT5A activation, each of the components was sequentially eliminated from the transfection. No combination of four cDNAs was sufficient to mediate significant IL-2-induced STAT DNA-binding activity ( Figure 6 , lanes 4-13). The low but detectable level of STAT5 induction observed in the absence of transfected IL-2Rβ receptor chains may be due to a low level of endogenous receptor chains. Therefore, IL-2Rβ, γ c , JAK1, JAK3 and STAT5A are necessary and sufficient to recapitulate IL-2-inducible STAT5A activation.
JAK1 and JAK3 catalytic functions are required for IL-2-mediated STAT5A activation
The U4A reconstitution system was next used to evaluate the JAK1 and JAK3 mutants in the context of IL-2-induced STAT5A activation. For JAK1, only wild-type JAK1 and the catalytically active JAK1YF mutant permitted full IL-2-induced STAT5A dimerization. In contrast, neither the JAK1K907A nor the JAK1FF mutant reconstituted STAT5A activation (Figure 7a , compare lanes 2,4,6). However, the JAK1FY mutant, which had no detectable function in the overexpression system, exhibited a very low but reproducible level of STAT5A induction in this assay system (Figure 7a, lane 8 ). These results demonstrate that STAT5A activation requires intact catalytic function of JAK1 and that the JAK1FY mutant may retain a small degree of catalytic potential.
In the case of JAK3, the JAK3K851A mutant failed to recapitulate IL-2-mediated STAT5 DNA-binding activity, demonstrating that JAK3 catalytic activity is critical for STAT5A. In contrast, both JAK3FY and JAK3YF, as well as JAK3FF, fully supported activation of STAT5A by the IL-2R (Figure 7b, lanes 6,8,10 ). All of these mutants thus retain biologically relevant catalytic function despite the lack of activation-loop tyrosines. Therefore, these regulatory mutants of JAK1 and JAK3 confirm that catalytic potential of both kinases is critical for IL-2-induced STAT5A activation.
Discussion
The JAK-STAT pathway was defined through a somatic genetic approach that demonstrated that the JAKs are epistatic to the STATs (reviewed in [10] [11] [12] 28] ). There is less evidence that JAKs directly phosphorylate STATs during receptor-mediated signaling [36, 42] . Immunoprecipitates of JAK1 and JAK3 phosphorylated wild-type MBP-STAT5A but failed detectably to phosphorylate MBP-STAT5A Y694F, supporting the hypothesis that JAKs can directly phosphorylate STATs. In addition, JAK1 phosphorylated STAT5A somewhat more efficiently than did JAK3 in vitro, suggesting that the JAKs may have different substrate specificities. Nonetheless, when overexpressed in COS-7 cells, JAK3 activated STAT5A DNAbinding activity. In this case, the high effective substrate concentration within the cell may overcome the lower substrate affinity that is physiologically relevant. Notably, JAK3FY did not phosphorylate STAT5A as effectively as the wild-type kinase in the COS-7 co-expression system, although this mutant reconstituted IL-2R function equivalently to wild-type JAK3. These results suggest that the role of JAK3 in the receptor complex may not be to phosphorylate STAT5 directly. Rather, it may normally serve to phosphorylate the receptor chains, JAK1, or another unidentified component involved in the initiation of signaling. Therefore, the difference revealed by the in vitro kinase assay may reflect a subtle but important difference in substrate specificity that is somewhat obscured in the overexpression system.
We next pursued the role of activation-loop tyrosines in JAK1 and JAK3 catalytic activation. The TYK2 Y1054F Y1055F mutant functions only at very high doses of IFN-γ [33] , and it remains unclear which of these two tyrosines is critical for kinase activation. As has been shown for JAK2 [32] , our studies demonstrate that the first tyrosine within the activation loop of JAK1 plays the dominant role in 4 5 6 7 8 9 10 11 12 13 Current Biology catalytic activation. JAK1YF behaved identically to the wild-type kinase in the assays we have used in this study. Activation-loop tyrosines may be sites of autophosphorylation or transphosphorylation, as the presence of these tyrosines also correlates with detectable tyrosine phosphorylation of JAK1. Alternatively, another kinase may phosphorylate the JAKs on these tyrosines, as with Bruton's tyrosine kinase (BTK), for which Src kinases initiate BTK activation by phosphorylating tyrosine 551 within the activation loop [43] . Furthermore, recent structural studies suggest that activation-loop phosphorylation may effect kinase activation by multiple mechanisms. In the insulin receptor kinase, an activation-loop tyrosine binds to the active site of the enzyme, thereby blocking substrate and ATP access [44] . In contrast, in the fibroblast growth factor receptor, the activation loop blocks the substrate-binding site, but not the ATP-binding site [45] . Moreover, the critical activation-loop determinants are not tyrosines but rather invariant amino acids. A precise understanding of the role of the activation loop in the regulation of JAK1 will await further structural characterization of the kinase domain.
In contrast to the other known JAKs, the catalytic activity of JAK3 was not strictly dependent on the presence of the activation-loop tyrosines. If phosphorylation of these tyrosines was essential for kinase activation, mutation of both tyrosines to phenylalanine would not have permitted catalytic function. Alternatively, phosphorylation might create docking sites for signaling intermediates containing SH2 or phosphotyrosine-binding domains. Ongoing studies are focused on clarifying the mechanism of JAK3 activation.
Analysis of JAK1-JAK3 chimeras demonstrated that kinase regulation cannot be mapped to a single domain. A chimeric molecule in which the amino terminus is derived from JAK3 and the kinase-like and kinase domains are derived from JAK1 was constructed in order to determine whether this chimera behaves like JAK1 or JAK3 with regard to the role of regulatory loop tyrosines in catalytic activation. The JAK3/1/1FF chimera, in contrast to JAK1FF, retained significant catalytic function. To test whether catalytic regulation is determined solely by the amino terminus of the molecule, we generated a series of JAK1/3/3 chimeras. The amino-terminal domain of these molecules appears to be properly folded, since the JAK1/3/3 chimera associated with the IL-2Rβ chain when these molecules were co-expressed in COS-7 cells. However, the JAK1/3/3 FF chimera functioned comparably to its wild-type parent. These findings suggest that the inherent catalytic function of the kinase domain plays a role in the regulation of kinase activity, since the kinase retained its catalytic function in the presence of the JAK1 amino-terminal domain. Taken together with the JAK3/1/1 chimera, which demonstrated that the amino-terminal portion of a JAK could influence its catalytic function, these data suggest that the regulation of kinase activity involves both interactions with the amino terminus of the molecule as well as the inherent potential of the kinase domain itself.
To create an experimental model in which both JAKs could be replaced in the IL-2R complex, essential components of the receptor were reconstituted in the somatic mutant human fibrosarcoma cell line U4A. In contrast to the previously described COS-7 overexpression system ( [25] ; K.D.L, unpublished observations), both JAK1 and JAK3 must be added to the U4A cellular background to reconstitute IL-2-inducible STAT5 activation. No mutant form of either JAK1 or JAK3 lacking catalytic function was capable of supporting signals leading to STAT5A DNA-binding activity following stimulation with ligand. Therefore, in contrast to the IFN-γ system [28] , it appears that the IL-2R complex fully requires two catalytically active JAKs for STAT5 activation. The specific regulation of these two kinases nonetheless appears to differ at the molecular level.
Conclusions
These studies investigated the potential regulatory role of conserved tyrosine residues present within the activation loops of JAK1 and JAK3. These tyrosines are required for JAK1 but not JAK3 function and therefore are likely to Research Paper IL-2 signaling and JAK phosphorylation Liu et al. 823
Figure 7
The IL-2R requires functional JAK1 and JAK3 for STAT5 activation. (a) U4A cells were transfected with the JAK1 mutants described in Figure 2 , in combination with IL-2Rβ, γ c , STAT5A and JAK3. WT, wild-type JAK1; KA, JAK1K907A; FF, JAK1FF ; FY, JAK1FY; and YF, JAK1YF. Cells were incubated with medium alone (-) or IL-2 (2) and nuclear extracts were prepared and subjected to EMSA. (b) EMSA of nuclear extracts prepared from U4A cells transfected with the JAK3 mutants described in Figure 3 along with IL-2Rβ, γ c , STAT5A and JAK1. WT, wildtype JAK3; KA, JAK3K851A; FF, JAK3FF; FY, JAK3FY; YF, JAK3YF. play fundamentally different roles in the regulation of activation. Since JAK3 does not require these tyrosines for catalytic function, ongoing studies are focused on the role of tyrosine phosphorylation in the regulation of JAK3 activation. We have also reconstituted functional IL-2R complexes in the U4A cell line, which lacks endogenous JAK1 and JAK3. These studies demonstrated that both JAK1 and JAK3 must be catalytically active in order for IL-2-induced STAT5 activation to occur. Although these findings highlight the potential importance of JAK1 in the activation of STAT5, further studies are needed to determine in more detail the relationships between the IL-2R chains, JAKs and their substrates.
Materials and methods
Cell lines
The COS-7 cell line was obtained from the American Type Culture Collection. These cells were passaged in Iscove's medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), L-glutamine, and 1% penicillin/streptomycin (P/S). For transient transfection studies, these cells were passaged in Dulbecco's modified Eagle medium supplemented with 10% FBS, L-glutamine, and 1% P/S. The U4A cell line was a generous gift from George Stark. Cell culture conditions for this cell line have been previously described [41] .
Reagents and antibodies
The antiphosphotyrosine antibody 4G10 and antibodies specific for JAK1 and JAK3 were obtained from Upstate Biotechnology. The polyclonal rabbit anti-STAT5A antibody was a generous gift from Xiuwen Liu and Lothar Heninghausen. The anti-Glu antibody coupled to Sepharose beads was a kind gift of Simon Cook. The cDNAs encoding murine JAK1 and JAK3 were a generous gift of James Ihle. The cDNA encoding STAT5A was a kind gift of Alice Mui. Recombinant human IL-2 was a gift of Chiron Corporation. The 561 hybridoma (the anti-IL-2Rβ antibody) was a kind gift of Paul Sondel. Competent DH5α cells were from Life Technologies. Pfu polymerase for PCR was obtained from Stratagene and deoxynucleotides were from Pharmacia.
Constructs and plasmids
Mutations generated by PCR were verified by DNA sequencing. The STAT5A Y694F mutant was created by PCR, cloned into pBS-STAT5A, and then transferred to the pCMV4HA vector. The cDNA encoding murine JAK1 was subcloned into pCMV4neo [46] . JAK1 was 3′ tagged with the Glu-Glu tag [47, 48] by introduction of a PCR product encoding the epitope hexapeptide (EYMPME, single-letter amino-acid code) into pJAK1neo. pJAK1FFneo, pJAK1FYneo, and pJAK1YFneo were generated by PCR. To prepare the JAK1K907A mutant, a double-stranded oligonucleotide encoding the mutation was introduced into pJAK1neo. The JAK3 cDNA was subcloned from pBSmuJAK3 into pCDM8dX and then transferred to pCMV4neo. A noncoding BamHI fragment was removed to create pJAK3neo. To create the epitope-tagged JAK3, the 3′ end of JAK3 was subcloned into pBS to create pBS3′JAK3, and a double-stranded oligonucleotide encoding the epitope tag was introduced. The JAK3K851A mutant was generated using a double-stranded oligonucleotide. The JAK3FF mutant was generated by PCR. The JAK3YF and JAK3FY mutants were generated with the Mutagene system (BioRad) and oligonucleotides encoding the appropriate mutations. Exchange of complementary sequences between JAK1 and JAK3 was used to generate the JAK3/1/1 and JAK1/3/3 chimeras. To create the JAK3/1/1 chimera, PCR was used to amplify the amino terminus of JAK3 with appropriate restriction sites and cloned into pJAK1neo. The sequence at the junction is as follows: FHTIP 516 578 LKKDI (italic sequences are derived from JAK3, bold sequences are from JAK1). Mutants were prepared by subcloning of the amino-terminal fragment of pJAK3/1/1neo into the appropriate pJAK1neo plasmids. To create the JAK1/3/3 chimera, the 5′ end of JAK3 was cloned into pBS and a unique AflII site was introduced. The 5′ end of JAK1 was subcloned into this construct. This JAK1/3 fusion was reintroduced into the context of full-length JAK3 (as well as into the JAK3 mutants). The sequence of the junction is as follows: DRILK 579 514DSLEW.
Fusion protein expression
The MBP-STAT5A fusions were created by cloning a blunted RsrII site-XbaI fragment of STAT5A that encodes the carboxy-terminal 157 amino acids in frame into the XmnI-XbaI sites of the pMAL-C2 vector (New England Biolabs). The fusion proteins were produced in DH5α and purified using amylose resin (New England Biolabs) per the manufacturer's instructions.
Transient transfection methods
COS-7 cells were transiently transfected using Lipofectamine (Life Technologies) as directed by the manufacturer. The U4A cell line was transiently transfected by the calcium phosphate method (Life Technologies) at a density of 2 × 10 6 per 100 mm plate.
Electrophoretic mobility shift assays
Nuclear extracts were prepared as described in [49] . Electrophoretic mobility shift assays were performed with 5 µg nuclear extract from COS-7 cells or 10 µg extract from U4A cells as described [15, 50] . Oligonucleotide probes were radiolabeled using polynucleotide kinase (Boehringer Mannheim) and γ-[ 32 P]ATP (Amersham) as described [51] .
Oligonucleotides and pre-incubation of nuclear extracts with anti-STAT5 antibodies are as described in [15] .
SDS-PAGE and western blotting
For expression studies, cells were lysed in 1 × SDS-PAGE loading buffer. Lysates were subjected to SDS-PAGE on 8.75% acrylamide gels, transferred to Immobilon-P (Millipore) or NitroPure (Micron Separations, Inc) and immunoblotted with the indicated antibodies. Chemiluminescent detection was performed with the ECL system (Amersham).
To verify equal protein loading, membranes were stripped and reprobed according to the manufacturer's instructions.
Immunoprecipitations
COS-7 cells were lysed in 1% NP-40 (Calbiochem), 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 µg ml -1 leupeptin, 10 µg ml -1 aprotinin, and 1 µg ml -1 pepstatin A. The lysates were precleared 3 × 30 min (561 antibody) or 2 × 60 min (JAK antibodies). Lysates were incubated with the appropriate antibody (2 µg for the 561 antibody, 5 µl for the anti-JAK1 and JAK3 antibodies) for 1 h, followed by addition of protein A beads (Boehringer-Mannheim) for 1 h. Beads were washed three times with lysis buffer and boiled with SDS-PAGE sample buffer.
In vitro kinase assays
Cells were collected in TEN buffer (150 mM NaCl, 40 mM Tris-HCl pH 7.5, 1 mM EDTA) and lysed in 1% NP-40 lysis buffer. Following immunoprecipitation with the anti-Glu beads, the beads were washed twice in lysis buffer and once in kinase buffer (0.5% NP-40, 140 mM NaCl, 25 mM Hepes pH 7.2, 1 mM MgCl 2 , 1 mM MnCl 2 , 2 mM sodium orthovanadate, 1 mM PMSF, 10 µg ml -1 leupeptin, 10 µg ml -1 aprotinin, and 1 µg ml -1 pepstatin A). Kinase reactions were initiated by adding 40 µl of kinase buffer supplemented with 1-10 mM cold ATP (Boehringer Mannheim), 10 µCi γ-[ 32 P]ATP (Amersham), and 2-5 µg substrate. Reactions were incubated at 37°C for 10 min and stopped by the addition of SDS-PAGE loading buffer. Following SDS-PAGE, proteins were visualized by Coomassie staining. The stained gel was subjected to autoradiography to assess phosphorylation.
